FEDERAL COURT OF AUSTRALIA
Juno Pharmaceuticals Pty Ltd v Millennium Pharmaceuticals, Inc
[2019] FCA 526
File number: VID 988 of 2018 Judge: BESANKO J Date of judgment: 16 April 2019 Catchwords: PRACTICE AND PROCEDURE — interlocutory application for leave to withdraw admissions — where the second respondent is registered as the owner of an Australian patent and as the exclusive licensee of an Australian patent — where the applicant supplies generic pharmaceutical products — where the applicant alleges that the second respondent’s patents are invalid on various grounds — where the second respondent cross-claims for patent infringement by the applicant’s generic products — where the applicant made certain admissions in its defence to the second respondent’s cross-claim — where the applicant now seeks to withdraw those admissions on the basis of an expert opinion
PRACTICE AND PROCEDURE — consideration of the principles relevant to whether to grant leave to withdraw an admission — consideration of the strength of the case now advanced that the admission is or may well be incorrect — whether the applicant has done all it could do to establish that the admission is incorrect — where the applicant could have, but has not yet, carried out an experiment which would or may well clarify whether the admission is incorrect — whether the applicant has acted in a transparent fashion — whether there has been a delay in making the application for leave to withdraw — whether the admission would have a significant impact on the respective cases of the parties if it is not withdrawn — consideration of case management principles and of the effect of the withdrawal of the admission on the trial date
Legislation: Federal Court of Australia Act 1976 (Cth) ss 37M, 37N
Hague Convention on the Service Abroad of Judicial and Extrajudicial Documents in Civil or Commercial Matters 1965
Cases cited: Ansell Healthcare Products LLC v Reckitt Benckiser (Australia) Pty Ltd (No 2) [2016] FCA 765
AON Risk Services Australia Ltd v Australian National University [2009] HCA 27; (2009) 239 CLR 175
Centrestate Exports Pty Ltd v Amarantos Shipping Co Ltd [2005] SASC 158
Jeans v Commonwealth Bank of Australia Ltd [2003] FCAFC 309; (2003) 204 ALR 327
Tamaya Resources Limited (in liq) v Deloitte Touche Tohmatsu (A Firm) [2016] FCAFC 2; (2016) 332 ALR 199
Date of hearing: 27 March 2019 Registry: Victoria Division: General Division National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Category: Catchwords Number of paragraphs: 51 Counsel for the Applicant: Mr T Cordiner QC with Mr C Smith Solicitor for the Applicant: Biopharmalex Counsel for the First Respondent: The First Respondent is excused from further participation in the proceedings until further order Counsel for the Second Respondent: Mr J S Cooke Solicitor for the Second Respondent: Davies Collison Cave Law Pty Ltd ORDERS
VID 988 of 2018 BETWEEN: JUNO PHARMACEUTICALS PTY LTD
Applicant
AND: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN…
Keep reading for free
Create a free CaseChat account to read Juno Pharmaceuticals Pty Ltd v Millennium Pharmaceuticals, I... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2019] FCA 526
- Decision Date
CaseChat Overview and Summary
The court considered the principles relevant to granting leave to withdraw an admission, focusing on the strength of Juno's case, the potential delay in the proceedings, and the transparency of Juno's actions. The court found that Juno had not yet conducted an experiment that could clarify the correctness of the admissions and had not acted transparently in delaying the application. Additionally, the court highlighted the importance of case management and the potential disruption to the trial date if the admissions were withdrawn. The expert opinion provided by Juno was deemed insufficient to warrant withdrawal of the admissions.
The Federal Court dismissed Juno's application for leave to withdraw the admissions. The reasoning underscored the need for a robust case demonstrating the incorrectness of the admissions, transparency in the proceedings, and consideration of the overall impact on the trial. The court emphasised the importance of adhering to case management principles and the potential disruption to the trial date.
The final orders of the court were that Juno's interlocutory application dated 5 March 2019 be dismissed.
Orders
Orders of the court
1. The applicant’s interlocutory application dated 5 March 2019 be dismissed.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.